Timothy Taylor, MD
Urology · Idaho Falls, IDNPI 1033121322
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,482 of the $3,191 with a category attached, or 77.8%. It is spread thinly across 36 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $696 and has fallen 86.4% since, to $95 in 2025. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.
Across 147 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$621
- Neotract Inc.$420
- AbbVie$292
- Johnson & Johnson$268
- Boston Scientific$249
- Antares Pharma, Inc.$137
- plus $1K from 30 others
What the payments were for
- Travel & lodging$31810%
- Food & beverage$2,48278%
- Education$39212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 24 | $621 |
| Neotract Inc. | 7 | $420 |
| AbbVie(2 entities) | 16 | $292 |
| Johnson & Johnson | 11 | $268 |
| Boston Scientific | 12 | $249 |
| Antares Pharma, Inc. | 12 | $137 |
| Pfizer | 7 | $121 |
| Endo Pharmaceuticals Inc. | 7 | $99 |
| Procept Biorobotics Corporation | 4 | $83 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Merck | 3 | $66 |
| Myovant Sciences Inc. | 4 | $60 |
| Laborie Medical Technologies Corp. | 2 | $56 |
| Teleflex LLC | 3 | $53 |
| 180 Medical, Inc. | 2 | $52 |
| Dendreon Pharmaceuticals LLC | 2 | $43 |
| Convatec Inc. | 2 | $39 |
| AstraZeneca | 2 | $39 |
| Urovant Sciences Inc | 2 | $38 |
| Immunitybio, Inc. | 2 | $38 |
| Axonics, Inc. | 2 | $36 |
| Endo USA, Inc. | 2 | $35 |
| Coloplast | 2 | $35 |
| Isoray, Inc | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Novartis | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Ambu Inc. | 2 | $19 |
| ABC Home Medical Supply, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Dornier Medtech America, Inc | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$318
How this compares
$3,191 in reported general payments places this provider in the 50th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $7,981 |
| Tolterodine Tartrate ErTolterodine Tartrate | 51 | $6,094 |
| Solifenacin Succinate | 13 | $4,500 |
| Tamsulosin Hcl | 300 | $3,417 |
| Potassium Citrate ErPotassium Citrate | 22 | $3,215 |
| Silodosin | 13 | $1,776 |
| Finasteride | 93 | $1,339 |
| Bicalutamide | 16 | $994 |
| Cephalexin | 36 | $825 |
| Dutasteride | 29 | $474 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $397 |
| Trimethoprim | 12 | $309 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $245 |
| Amoxicillin | 17 | $156 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $621 | $7,98118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 urology providers in Idaho.
Other urology in Idaho Falls
- Richard BlatterIdaho Falls$5K
- Jared ManwaringIdaho Falls$4K
- Duncan HarrisIdaho Falls$3K
- Roger TallIdaho Falls$7
- Peter CannonIdaho Falls$4
- Sean StroupBoise$93K
- Zachary GlaserTwin Falls$15K
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.